

Realising the Commercial Potential of Therapeutic Antibodies

Incorporating the very latest advancements in antibody development to ensure sustainable profit growth

- Implement breakthrough research in antibody engineering for enhanced effector functions to **maximise ROI through effective drug development**
- **Reduce time to market** by establishing best practices for agnostic and antagonistic antibodies
- **Benchmark and improve your R&D processes** by hearing from William Strohl, Merck, on expanding indications for antibody therapy through improved delivery
- Incorporate the very latest antibody developments in various therapeutic areas to **minimise discovery timelines**

Book online @ www.iqpc.com/uk/antibodies

PLUS! Join Dr Frank Carr, Director, Biologics Research, Antitope Ltd, at our interactive evening workshop on 30th September for a detailed analysis of Preclinical Immunogenicity testing of Protein Therapeutics

Your expert speaking faculty includes:

- William Strohl - Executive Director, Department of Biologics Research, Merck
- David Blakey - Senior Principal Scientist, AstraZeneca
- Dr Alastair Lawson - Director of Antibody Technology, UCB Celltech
- Dr Horst Lindhofer - Chief Executive Officer, TRION Pharma
- Dr Mike Clark - Reader in Therapeutic and Molecular Immunology, University of Cambridge
- Matthew Baker - Chief Scientific Officer, Antitope
- Professor Agamemnon Epenetos - Consultant Oncologist, Trojan Technologies
- Dr Nils Lonberg - SVP Scientific Director, Medarex
- Dr Victor S. Goldmacher - Senior Director, Cell Biology, ImmunoGen
- Dr Jerry W. Slootstra - Director Epitope Mapping and Protein Mimicry, Pepscan
- John Haurum - Chief Scientific Officer, Symphogen
- Philippe Stas - Chief Executive Officer, AlgoNomics
- Professor Dr Stefan Dübel - Institute of Biochemistry and Biotechnology, Technical University of Braunschweig
- Dr Kerry Chester - Oncology Department, UCL Cancer Institute
- Dr Michel Cogné - Managing Director, Université de Limoges et Centre Hospitalier Universitaire Dupuytren

NETWORKING
SPONSOR



Piramal Healthcare
knowledge action care

30th September to 1st October - Café Royal, London



Why Should You Attend?

Pharma IQ's **Therapeutic Antibodies** will examine strategies employed by both biotechnology and pharmaceutical companies. Discussions will cover the advantages and limitations of antibody-based products as well as patent issues and applicability.

Cutting-edge technological advances coupled with the implementation of innovative engineering techniques have expanded antibody function and improved the efficacy of antibody drugs in development. With basic research into novel therapeutic applications increasing, the move into niche markets offers huge potential for growth.

Key Topics to be Covered Include:

- ✓ **Real-life case studies** from your industry peers, featuring their challenges and solutions, allowing you to learn from their experiences and **gain practical insights** for your future developments
- ✓ **Breakthrough research** in antibody engineering for enhanced effector functions
- ✓ **Recent antibody developments** in specially selected areas including oncology, infectious diseases, inflammatory diseases and CNS
- ✓ Innovative ideas on **expanding indications** for antibody therapy through **improved delivery**
- ✓ Best practices for **agonistic** and **antagonistic antibodies**

Who Will You Meet?

Representatives drawn from the pharmaceutical and biotech industry including:

Vice Presidents, Directors, Head and Managers of:

- | | |
|-----------------------------------|-------------------------------|
| ❖ Research and Development | ❖ Oncology |
| ❖ Pre-clinical development | ❖ Drug Discovery |
| ❖ Clinical Development | ❖ Antibody Engineering |
| ❖ Antibody Development | ❖ Protein Engineering |
| ❖ Product Development | ❖ Immunology |
| ❖ Manufacturing | ❖ Clinical Diagnostics |

Interactive Evening Workshop - 30th September 18:20-20:00

PRECLINICAL IMMUNOGENICITY TESTING OF PROTEIN THERAPEUTICS

Led by Dr Frank Carr, Director for Biologics Research at Antitope Ltd. This practical workshop will provide a more detailed and practical experience of immunogenicity testing.

Agenda

- * Immunogenicity - the basics
- * Current/future approaches to preclinical testing
- * What do the regulators want?
- * Improved design of biomolecules to avoid immunogenicity

Objectives

The workshop objective will be to discuss the advantages and disadvantages of current and future approaches to preclinical testing of protein therapeutics in order to assess immunogenic potential. In particular, questions addressing the type of tests and study design will be discussed with regard to facilitating regulatory approval. The workshop will also discuss biomolecular and clinical approaches to reducing or avoiding immunogenicity in protein therapeutics.

CONFERENCE DAY 1

8:30 Registration and Refreshments

THE BURGEONING BUSINESS OF ANTIBODIES

9:00 Opening Remarks From the Chair

Dr Mike Clark
Reader in Therapeutic and Molecular Immunology
University of Cambridge

9:10 Exploring the Changing Landscape, Drivers and Demand for Therapeutic Antibodies

- Examining the impact of emerging next generation antibody technologies on key trends in the market
- Analysing the factors underlying the M&A trend between pharma and biotherapeutics focused biotech companies and the market implications
- Determining the pros and cons of acquisition vs. licensing approaches for securing access to next generation antibody technologies
- Examining the prospects of next generation antibody technology in providing the next wave of blockbuster products:
 - where are the likely advances in innovation?
 - quantifying the threat from biosimilars
- Forecasting the biotherapeutic landscape and identifying the commercial opportunities and threats to key players

William Strohl
Executive Director
Department of Biologics Research, Merck

CUTTING EDGE ANTIBODY ENGINEERING DEVELOPMENTS

9.45 Assessing Developments and Advances in the Discovery of Antibody Biopharmaceuticals

- Variable region discovery
- Utilising antibodies as tools in the drug discovery process
- Evaluating the value of research reagents
- Analysing information from the binding of function-modifying antibodies to inform a new generation of small molecule drugs

Dr Alastair Lawson
Director of Antibody Technology
UCB Celltech

10.20 PHARMA IQ'S INSTANT ADDRESS BOOK, SPONSORED BY  Piramal Healthcare

Expand your network of business contacts dramatically in just 45 minutes with our fun, fast paced, structured networking session

11.05 Morning Refreshments

11:35 Engineering Antibody Fc Regions to Optimise Safety and Efficacy

- Understanding the need for improved receptor binding
- Engineering the antibody Fc region for optimal interaction with a variety of Fc receptors
- Applying advanced technologies to create clinical candidates

Dr Mike Clark
Reader in Therapeutic and Molecular Immunology
University of Cambridge

12:10 Tailoring Antibodies for the Clinic: Engineering the Antibody Effector Function and Enabling Novel Mechanisms

- Understanding the trifunctional mode of action
- Examining the results of pivotal phase II/III study
- Reviewing the roll out of clinical development program

Dr Horst Lindhofer
Chief Executive Officer
TRION Pharma

12:45 Lunch

14:00 Reviewing the Current Intellectual Property Situation Relating to Antibodies

- Understanding how to protect antibodies through patenting
- Examining recent developments in the granting of patents to antibodies
- Building an antibody patent portfolio
- Strategies for enforcing patents to antibodies
- Determining a reasonable scope of protection for an antibody claim
 - How can you avoid infringing competitor antibody patents?
- Assessing the implications and impact of antibody patents on the biotechnology industry

Dr Philip Webber
European Patent Attorney
Frank B. Dehn & Co.

THE FUTURE DIRECTION OF THE ANTIBODIES MARKET

14:45 Promoting Antibody Selection Against Novel Protein Targets Through Protein Mimics

- Mapping of discontinuous epitopes and complex receptor-ligand binding sites
- Selecting highly potent immunogens that induce antibodies that recognise the native antigen
- Forecasting future trends in selection of antibodies against "impossible targets"(GPCR's) through synthetic protein mimics

Dr Jerry W. Sloodstra
Director Epitope Mapping and Protein Mimicry
Pepsan

15:30 Afternoon Coffee

16:00 Applying Cutting-Edge Antibody Engineering For the Development of New Generation of Humanised Antibodies

- The potential use of therapeutic IgA antibodies.
- Developing next generation antibodies with enhanced effector functions
- Achieving Fc antibody-dependent cellular cytotoxicity through Fc glycoengineering
- Applying enhanced apoptosis induction

Dr Michel Cogné, MD, PhD
Université de Limoges et Centre Hospitalier
Universitaire Dupuytren

16:45 Examining Novel Formats and Applications of Antibody Fragments

- scFab - developments and applications
- Fab fragments
- Single chain variable fragments
- Extended release formulations

Professor Dr Stefan Dübel
Institute of Biochemistry and Biotechnology
Technical University of Braunschweig

17:15 Lessons Learnt from Case Studies on Antibody Therapeutics

- Understanding the failure of preclinical safety testing and the disastrous phase 1 clinical trial of TGN1412
- Examining a potentially fatal "cytokine storm", not predicted in preclinical testing, occurred during the clinical trial of the therapeutic antibody TGN1412
- Developing novel in vitro procedures that reveal the toxicity of this superagonist during safety testing

Dr Richard Stebbings
Principal Scientist, Transfusion Medicine Section
Biotherapeutics Group, National Institute for
Biological Standards and Control

18:00 Closing Remarks from the Chair

18:10 End of Conference Day One

CONFERENCE DAY 2

8:30 Registration and Refreshments

9:00 **Opening Remarks From the Chair**

William Strohl
Executive Director
Department of Biologics Research
Merck

THE CHALLENGES OF RISK ASSESMENT AND IMMUNE RESPONSE

9:15 **Implementing Practical Measures for Reducing Antibody Immunogenicity**

- Addressing the challenges of antibody immunogenicity
- Identifying factors that influence immunogenicity of therapeutic proteins
- Determining the relative immunogenicity of proteins
- Demonstrating the association of T cell epitopes with immunogenicity
- Lessons learnt from case studies on antibody therapeutics

Philippe Stas
Chief Executive Officer
AlgoNomics

10:00 **Immunogenicity Risk Assessment and Regulatory Guidelines**

- Developing strategies for immunogenicity identification and testing
- How to conduct a risk assessment
- Immunoprofiling via epitope identification
- Analysing new technologies allowing the selection of lead biologics with lower risk

Matthew Baker
Chief Scientific Officer
Antitope

10:45 Morning Refreshments

11:15 **Examining Developments in Targeting Co-stimulatory Pathway Molecules for Antibody Immunotherapy**

- Using antibody blockade of co-stimulatory pathway molecules for immune stimulation
- Combining multiple antibody drugs to overcome tolerance to weak immunogens such as tumor antigens
- Exploiting tumor specific expression of co-stimulatory pathway molecules for targeting antibody-drug conjugates

Dr Nils Lonberg
SVP Scientific Director
Medarex

NEW THERAPEUTIC AREAS: HOW CAN ANTIBODIES HELP?

12:00 **Developing Improved Antibody-Effector Conjugates for Cancer Therapy**

- Examining innovations in antibody conjugation
- Analysing types of conjugation:
 - direct arming: antibody conjugation
 - indirect arming: bispecific monoclonal antibodies
 - indirect arming: antibody-directed enzyme prodrug therapy
- Understanding the design parameters for antibody drug conjugates
- Evaluating preclinical performance

Dr Kerry Chester
Oncology Department
UCL Cancer Institute

12:45 Lunch

14:00 **Developments in Cancer Stem Cells and Discussing Possible Targets and Therapeutic Antibodies**

- Reviewing the concept of using antibodies in oncology and against cancer stem cells
- Examining mAb products in clinical development
- Developing strategies for design of mAb products

Professor Agamemnon Epenetos
Consultant Oncologist
Trojan Technologies

14:45 **Developments in Antibody Development and Research in Oncology**

- Reviewing the development of therapeutic antibodies in oncology
- Utilisation of transgenic mouse and display technologies for generating and optimising therapeutic antibodies
- Experience of building an oncology portfolio in AstraZeneca/Medimmune using these technologies

David Blakey
Senior Principal Scientist
AstraZeneca

15:30 Afternoon Coffee

16:00 **Case Study: Immunoconjugates of Maytansinoids for the Treatment of Cancer**

- Examining antibody-targeted cytotoxic agents
- Analysing the design, properties, molecular mechanisms of action
- Pre-clinical/clinical development of antibody-cytotoxic agent conjugates for the treatment of cancer

Dr Victor S. Goldmacher
Senior Director, Cell Biology
ImmunoGen

16:45 **Examining the Use of Human Monoclonal Antibodies as Anti-Infective Drugs**

- Reviewing the concept of using antibodies in infectious diseases
- Examining anti-infective mAb products in clinical development
- Developing strategies for design of anti-infective mAb products

John Haurum
Chief Scientific Officer
Symphogen

17:30 Closing Remarks from the Chair

17:40 End of Conference



Realising the Commercial Potential of

Therapeutic Antibodies

Balancing Technology Development with Profitability



Sponsorship Opportunities

Contract services organisations! - Your antibody market needs YOU!

This meeting will attract pharmaceutical companies, biotechs and antibody developers looking for solutions to their development challenges. Sponsors for this event will have the opportunity to meet a wide variety of these professionals in one place over a two day programme.

In this environment of budget-tightening, as the economy supposedly slows down, it is more and more important to allocate your spend to areas that are going to yield the largest results. No other promotional vehicle offers you the chance to achieve all of the following key objectives in one.

'Realising the commercial potential of therapeutic antibodies' will help you:

- Get cost-effective marketing exposure and branding to your target audience, culminating in face-to-face meetings with your best prospects.
- Position and profile yourself as an industry leader.
- Increase your brand recognition in the global antibody industry.
- Create new partnerships and alliances.
- Develop relationships through new networking opportunities.
- Showcase new products and services to a targeted audience of decision-makers.
- Get direct and exclusive access to global antibody development leaders.

For more information on how you can achieve your promotional goals, please call +44 (0) 20 7368 9300

NETWORKING SPONSOR



Piramal Healthcare

knowledge action care

With a 20 year history in cytotoxics, **Piramal Healthcare** has 5 years experience in the GMP manufacture of antibody-drug conjugates, and a 100% right first time track record, across 5 production suites. Our conjugation experts can develop processes from conception to commercialisation, demonstrating safe and seamless scale-up. For more information please call Nick Evens on 01324 494 527 or email at nick.evens@piramal.com

MEDIA PARTNERS



Autoimmune Drug Focus

Anti-Infective Drug News

Cancer Drug News



Realising the Commercial Potential of Therapeutic Antibodies

- 30th September to 1st October, The Café Royal, London -

REGISTRATION FORM

To speed registration, please provide the priority code located on the mailing label or in the box below.

My registration code is

Please contact our database manager on +44(0) 207 368 9300 or at database@iqpc.co.uk quoting the registration code above to inform us of any changes or to remove your details.



Web: www.iqpc.com/uk/antibodies



Phone: +44 (0) 20 7368 9300



Fax: +44 (0) 20 7368 9301



Email: enquire@iqpc.co.uk



Post: IQPC Ltd. Anchor House,
15-19 Britten Street,
London, SW3 3QL, UK

Team Discounts

IQPC recognises the value of learning in teams. Groups of 3 or more booking at the same time from the same company receive a 10% discount. 5 or more receive a 15% discount. 7 receive a 20% discount. Only one discount available per person.

Venue & Accommodation

VENUE:

The Café Royal (no accommodation)
68 Regent Street, London W1B 5EL
Tel: +44 (0) 20 7437 9090

ACCOMMODATION:

Overnight accommodation is not included in the registration fee. However, reduced rates are available at **Le Meridien Piccadilly**. For Le Meridien Piccadilly Tel: +44 (0) 20 7851 3344, always quote GA1 or book online: www.lemeridien.com/GA1. Prices from £200 + vat (room only). Or for **Thistle Marble Arch** tel: +44 (0) 870 414 1516 and press '1'. Quote booking reference GA2. Prices from £111 + vat. Or for further hotels search: www.cityhotelaccommodation.com

STANDARD INDUSTRY RATES

Please Tick	CONFERENCE PACKAGE	Early Bird Price* – Book and pay by 27th June 2008	Early Bird Price* – Book and pay by 25th July 2008	Standard Price Per Person
<input type="radio"/>	Gold Package (Conference + Workshop)	£1698 + VAT** Save £200	£1798 + VAT** Save £100	£1898 + VAT**
<input type="radio"/>	Conference only	£1199 + VAT** Save £200	£1299 + VAT** Save £100	£1399 + VAT**
<input type="radio"/>	Workshop only			£499 + VAT**

50% Academic Discount

* In order to qualify for discounts, bookings must be received with payment by the discount dates. Only one discount is applicable per person.

** UK VAT is charged at 17.5% and will be assessed and added to the total amount due. UK VAT registration no. GB 799 2259 67

Delegate Information

DELEGATE 1 Mr Mrs Miss Ms Dr Other

First Name

Family Name

Position

Email

Organisation

Address

Tel Fax

Cancellations & Substitutions

PAYMENT is due in full upon completion and return of the registration form. Due to limited conference space we advise early registration and payment by credit card to avoid disappointment. Your registration will not be confirmed until payment is received. Admission to the conference will be refused if payment has not been received.

CANCELLATION AND SUBSTITUTION POLICY Provided the fee has been paid in full, substitutions at no extra charge can be made up to 7 business days before the start of the conference. Cancellations must be received in writing or by fax to +44 (0)20 7368 9301, more than 7 days before the conference is to be held in order to obtain a full credit for any future conference. Cancellations received 7 days or

less (including the seventh day) prior to the conference will not be credited. In the event that IQPC cancels an event payments received at the cancellation date will be credited towards attendance at a future conference, or in the event of postponement by IQPC, a rescheduled date. Credit notes remain valid for twelve months. IQPC reserves the right to postpone or cancel an event, to change the location of an event or to alter the advertised speakers for an event. IQPC is not responsible for any loss or damage as a result of substitution, alteration, postponement, or cancellation of an event due to causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism, or hostilities.

SPEAKER CHANGES Occasionally it is necessary for reasons beyond our control to alter the content and timing of the programme or the identity of the speakers

DATA PROTECTION Personal data is gathered in accordance with the Data Protection Act 1998. Your details may be passed to other companies who wish to communicate with you offers related to your business activities. If you do not wish to receive these offers, please tick the box below.

Please do not pass my information to any third party

© IQPC Ltd. 2008
UK VAT registration no. GB 799 2259 67

Payment Methods

Total Price for your Organisation: _____

(Add total of all individuals attending): _____

Card Number: VISA M/C AMEX

Exp. Date: Sec:

Name On Card: _____

Signature: _____

Billing Address (if Different From below): _____

City/County/Postcode _____

Cheque enclosed for: £ _____
(Made payable to IQPC Ltd.)

By Direct Transfer: IQPC Bank Details: HSBC Bank, 67 George

Street, Richmond, Surrey, TW9 1HG Sort Code: 40-38-18

Account No: 51304143 Account Name: IQPC Ltd IBAN No:

GB59MIDL40381851304143 Swift Code: MIDLGB2112V

Ref: Please include name of the attendee(s) and the number:

13772.001

Digital Conference on CD ROM

A digital version of the conference proceedings, including all the presentations in audio format

"An excellent service, an invaluable reference tool, easy to access and easy to store – all in all a top product"

Recent digital conferences available – £599 + VAT each

EPCM

Pharmacovigilance

Personalised Medicine

Please send me conference materials indicated above.
I have filled out credit card details above

For further information please call: 0207 368 9300
or email: knowledgebank@iqpc.co.uk.

To search IQPC's archived conference documentation, visit:
www.iqpcknowledgebank.com

PAYMENT MUST BE RECEIVED PRIOR TO THE CONFERENCE